Document Detail


Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery.
MedLine Citation:
PMID:  2754275     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Amiodarone (AD) induces photosensitivity in 75% of the patients treated with this drug. Phototoxic reactions can be experimentally elicited with UVA but not with UVB. The UVA-MED is significantly reduced after 12 months of treatment. The development of photosensitivity depends on the total dose of AD; 40 g is the minimal cumulative dose requirement. Under the regimens commonly used, photosensitivity can be expected after 4 months of continuous AD treatment and appears to be unrelated to the skin type. Photosensitivity gradually decreases and returns to normal between 4 and 12 months after the withdrawal of AD. AD-related hyperpigmentation develops after an average of 20 months of continuous AD treatment and a minimal total dose of 160 g AD in about 8% of the patients (mainly of skin type I). Electron microscopic examination of the sun-exposed skin of patients without AD discoloration shows pigment deposits similar to those already described in patients with AD hyperpigmentation in exposed and non-exposed skin. Light and electronmicroscopic examination of sun-exposed skin of both clinically photosensitive and non-photosensitive patients reveals perivascular inflammation even in the absence of a clinical rash. Reduplications of vascular basal laminae occur in sun-exposed skin of both patients with and without UVA photosensitivity but are absent from non-exposed skin. In one patient, followed for 33 months after drug withdrawal, massive AD-induced hyperpigmentation was found to be reversible.
Authors:
K Rappersberger; H Hönigsmann; B Ortel; A Tanew; K Konrad; K Wolff
Related Documents :
18582825 - Dynamic compression system for the correction of pectus carinatum.
21717175 - Women with high telomerase activity in luteinised granulosa cells have a higher pregnan...
8407415 - Total skin electron therapy: a technique which can be implemented on a conventional ele...
18349665 - Percutaneous collagen induction therapy: an alternative treatment for scars, wrinkles, ...
24642585 - Vocal process granulomas: a systematic review of treatment.
23079565 - Pruritus in adult burn survivors: postburn prevalence and risk factors associated with ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  93     ISSN:  0022-202X     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  1989 Aug 
Date Detail:
Created Date:  1989-09-01     Completed Date:  1989-09-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  201-9     Citation Subset:  IM    
Affiliation:
Department of Dermatology I, University of Vienna, Medical School, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amiodarone / adverse effects*
Face
Humans
Microscopy, Electron
Photosensitivity Disorders / chemically induced*,  pathology
Pigmentation Disorders / chemically induced*,  pathology
Radiation Injuries
Skin / pathology,  ultrastructure
Sunlight / adverse effects
Time Factors
Ultraviolet Rays / adverse effects
Chemical
Reg. No./Substance:
1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Generation of C5-dependent bioactivity by tissue-bound anti-BMZ autoantibodies.
Next Document:  Cutaneous papillomatous hyperplasia in cyclosporine-A treated beagles.